These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20606311)

  • 1. Efficacy of combination treatment and influence of schedule with irinotecan and amrubicin in human lung carcinoma cells in vivo and in vitro.
    Shishido Y; Furuta T; Matsuzaki T; Nagata H; Hashimoto S
    Biol Pharm Bull; 2010; 33(7):1183-91. PubMed ID: 20606311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
    Hanada M; Noguchi T; Yamaoka T
    Cancer Sci; 2007 Mar; 98(3):447-54. PubMed ID: 17214744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
    Takigawa N; Takeyama M; Shibayama T; Tada A; Kawata N; Okada C; Aoe K; Kozuki T; Hotta K; Tabata M; Kiura K; Ueoka H; Tanimoto M; Takahashi K
    Oncol Rep; 2006 Apr; 15(4):837-42. PubMed ID: 16525668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
    Harada T; Hamada A; Shimokawa M; Takayama K; Kudoh S; Maeno K; Saeki S; Miyawaki H; Moriyama A; Nakagawa K; Nakanishi Y
    Jpn J Clin Oncol; 2014 Feb; 44(2):127-33. PubMed ID: 24379211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
    Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
    J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro schedule-dependent interaction between irinotecan and vinorelbine in NCI H460 non-small cell lung cancer cell line.
    Gauvin A; Bressolle F; Martineau P; Astre C; Pinguet F
    Anticancer Res; 2002; 22(2A):905-12. PubMed ID: 12014670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
    Asakuma M; Yamamoto M; Wada M; Ryuge S; Katono K; Yokoba M; Fukui T; Takakura A; Otani S; Maki S; Igawa S; Yanaihara T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1529-36. PubMed ID: 22415148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
    Yanaihara T; Yokoba M; Onoda S; Yamamoto M; Ryuge S; Hagiri S; Katagiri M; Wada M; Mitsufuji H; Kubota M; Arai S; Kobayashi H; Yanase N; Abe T; Masuda N
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):419-27. PubMed ID: 16832665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
    Nogami N; Hotta K; Segawa Y; Takigawa N; Hosokawa S; Oze I; Fujii M; Ichihara E; Shibayama T; Tada A; Hamada N; Uno M; Tamaoki A; Kuyama S; Ikeda G; Osawa M; Takata S; Tabata M; Tanimoto M; Kiura K
    Acta Oncol; 2012 Jul; 51(6):768-73. PubMed ID: 22283472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
    Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
    Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1055-60. PubMed ID: 9849585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
    Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
    Int J Cancer; 2010 Dec; 127(11):2699-706. PubMed ID: 20198621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy.
    Hatakeyama Y; Kobayashi K; Nagano T; Tamura D; Yamamoto M; Tachihara M; Kotani Y; Nishimura Y
    Cancer Lett; 2014 Feb; 343(1):74-9. PubMed ID: 24139969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of amrubicin with a 5 day administration schedule in a mouse model].
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Gan To Kagaku Ryoho; 1999 Aug; 26(9):1305-12. PubMed ID: 10478184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
    Satouchi M; Kotani Y; Shibata T; Ando M; Nakagawa K; Yamamoto N; Ichinose Y; Ohe Y; Nishio M; Hida T; Takeda K; Kimura T; Minato K; Yokoyama A; Atagi S; Fukuda H; Tamura T; Saijo N
    J Clin Oncol; 2014 Apr; 32(12):1262-8. PubMed ID: 24638015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
    Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].
    Kurai J; Igishi T; Suyama H; Kodani M; Fukuoka Y; Miyata M; Touge H; Hasegawa Y; Yasuda K; Hitsuda Y; Shimizu E
    Gan To Kagaku Ryoho; 2006 Mar; 33(3):373-5. PubMed ID: 16531722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
    Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
    J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
    Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
    Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.